bioAffinity Technologies
BIAF
15 hedge funds and large institutions have $499K invested in bioAffinity Technologies in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.
1,337% more capital inflows, than outflows
Capital inflows: $98.4K | Capital outflows: $6.85K
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
25% more funds holding
Funds holding: 12 → 15 (+3)
0.03% less ownership
Funds ownership: 3.48% → 3.45% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
+$35.6K |
| 2 |
Two Sigma Securities
New York
|
+$19.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.3K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$5.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.04K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$604 |
| 3 |
Clear Street
New York
|
-$208 |
BIAF Hedge Fund Activity: Q4 2024 in Review
15 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q4 2024, worth a combined $499K — down 49% from $975K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIAF positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Sheaff Brock Investment Advisors, adding an estimated $35.6K. The largest seller was Morgan Stanley, cutting an estimated $6.04K.
- 15 institutional investors held bioAffinity Technologies (BIAF) as of Q4 2024, up from 12 in Q3 2024.
- Funds reported $499K of bioAffinity Technologies stock for Q4 2024, down 49% quarter-over-quarter.
- 3 funds opened new bioAffinity Technologies positions in Q4 2024 and 0 closed out, a net change of +3 holders.
- The largest bioAffinity Technologies buyer in Q4 2024 was Sheaff Brock Investment Advisors, an estimated $35.6K added.
- The largest bioAffinity Technologies seller in Q4 2024 was Morgan Stanley, an estimated $6.04K sold.
Based on aggregated 13F filings for Q4 2024.